Our Virtual Satellite Symposium provides an expert discussion of the challenges and new opportunities in the management and treatment of patients with Waldenström’s macroglobulinemia, a complex B-cell malignancy.
Introduced and chaired by Prof. Christian Buske (Medical Director of the Comprehensive Cancer Center Ulm (CCCU) and the Institute of Experimental Cancer Research at the Universitätsklinikum Ulm, Germany), the symposium explores key aspects of the disease, and features a panel discussion with a focus on new treatments.
Dr. Roger Owen (Consultant in Clinical Hematology and Hematopathology at St. James’s Institute of Oncology, with the Leeds Teaching Hospitals NHS Trust, UK) describes the discovery of Waldenström’s, and presents key aspects of diagnosis, prognosis and disease monitoring. He provides a clear view of clinical and genetic features of the malignancy, and the diagnostic process.
Prof. Véronique Leblond (Professor in Hematology at Sorbonne University and Head of the Department of Hematology at Pitié Salpêtrière Hospital in Paris, France) provides an overview of current treatments, considering drivers of treatment choice, the best options in treatment-naïve and relapsed/ refractory Waldenström’s, and tailored, genomic-driven treatment. She presents treatment algorithms for newly diagnosed Waldenström’s and symptomatic relapse.
Dr. Alessandra Tedeschi (Consultant in Hematology and Medical Director of the Department of Hematology at the Niguarda Cancer Center in Milan, Italy) explores new and emerging treatment options, including BTK inhibitor pharmacokinetics and results from recent clinical trials of Zanubrutinib, Acalabrutinib and Venetoclax.
As an additional insight, speakers provide personal opinions and future perspectives, and answer questions from Prof. Buske who also provides an executive summary, conclusions and key messages.